Table 3.
Treatment | Plasma Atherogenic indices | ||
---|---|---|---|
AI | CRI | HDL-c/LDL-c | |
Sham (Group I) | 3.44 ± 0.59 | 3.55 ± 0.22 | 0.62 ± 0.05 |
OVX | 4.71 ± 0.55 | 4.65 ± 0.33# | 0.3 ± 0.04 |
OVX + TSO | 6.03 ± 1.02# | 5.57 ± 0.49# | 0.36 ± 0.06 |
OVX + TSO + ATV | 3.43 ± 0.41*** | 3.74 ± 0.52*** | 1.25 ± 0.32*** |
OVX + TSO + EZE + ATV | 3.86 ± 0.94*** | 4.90 ± 0.67 | 0.45 ± 0.11 |
OVX + TSO + ETD | 4.04 ± 0.64** | 3.64 ± 0.38*** | 0.18 ± 0.31 |
Values are expressed as mean ± SEM (n = 6)
#p < 0.05 compared to Group I values accepted as significant
*p < 0.05 compared to OVX + TSO
**p < 0.01 compared to OVX + TSO
***p < 0.001 compared to OVX + TSO
OVX – ovariectomized; TSO – thermoxidized soya oil; ATV – atorvastatin; EZE – ezetimibe; ETD – estradiol; HDL-c – high density lipoprotein cholesterol; LDL-c – low density lipoprotein cholesterol; AI – atherogenic index; CRI – coronary risk index